The t(16;21)(q24;q22) translocation is a rare but recurrentchromosomal abnormality associated with therapy-related myeloidmalignancies. The translocation produces a chimeric gene made up of the 5'-region of theAML1 gene fused to the 3'-region of this gene. In addition, this gene is a putative breasttumor suppressor. Two transcript variants encoding different isoforms have been found for this gene, and abrefeldin A-sensitive association of RII-alpha protein with one of the isoforms has been demonstrated in theGolgi apparatus.[6]
^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^Calabi F, Cilli V (Dec 1998). "CBFA2T1 (core-binding factor, runt domain, alpha subunit 2; translocated to, 3), a gene rearranged in human leukemia, is a member of a multigene family".Genomics.52 (3):332–41.doi:10.1006/geno.1998.5429.PMID9790752.
^Lindberg SR, Olsson A, Persson AM, Olsson I (Dec 2003). "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins".Eur. J. Haematol.71 (6):439–47.doi:10.1046/j.0902-4441.2003.00166.x.PMID14703694.S2CID23106882.
Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M (1998). "The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family".Blood.91 (11):4028–37.doi:10.1182/blood.V91.11.4028.PMID9596646.
Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y, Kinoshita A, Ohki M, Tomita Y, Mori T (2003). "A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene".Leuk. Lymphoma.43 (2):415–20.doi:10.1080/10428190290006242.PMID11999578.S2CID23133496.
Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen AM, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G,Sutherland GR, Callen DF (2002). "CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3".Cancer Res.62 (16):4599–604.PMID12183414.
Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA,Sutherland GR, Callen DF, Kremmidiotis G (2003). "Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes".Genomics.80 (3):303–10.doi:10.1006/geno.2002.6828.PMID12213200.
Lindberg SR, Olsson A, Persson AM, Olsson I (2004). "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins".Eur. J. Haematol.71 (6):439–47.doi:10.1046/j.0902-4441.2003.00166.x.PMID14703694.S2CID23106882.
